ALFA FinderBSE filing, NSE: ICICIAMC. Summary written from the filing by ALFA Finder's alert engine.
ICICI Prudential Asset Management Company Ltd: key numbers
- Share price
- ₹2,970.80
- Market cap
- ₹1,46,834 Cr
- Revenue (annual)
- ₹5,999 Cr
- Net profit (annual)
- ₹3,298 Cr
- P/E (TTM)
- 41.5×Sector 20.5×
- Promoter holding
- 85.60%-2.00% QoQ
- FII holding
- 3.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from ICICI Prudential Asset Management Company Ltd
All →ICICI Prudential Asset Management Company Other Announcement
ICICI Prudential AMC intimates that its RTA, KFin Technologies, moves its corporate office effective 1 December 2026. Investors should update correspondence records to the new Hyderabad address.
ICICI Prudential Asset Management Company Management Change
ICICI Prudential AMC disclosed that Senior Management Personnel Anand Shah resigned, ceasing to be SMP after November 12, 2026. The resignation is a personnel change, with no monetary impact.
ICICI Prudential Asset Management Company Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
ICICI Prudential Asset Management Company Earnings Call Transcript: Key Takeaways
Operating revenue grew 16.3% YoY to ₹1,674 Cr, though mark-to-market hits on treasury dragged PAT down 7.8% QoQ.
ICICI Prudential Asset Management Company Dividend
ICICI Prudential Asset Management Company declared an interim dividend of ₹30 per equity share for FY 2026-27. The record date is October 21, 2026.
ICICI Prudential Asset Management Company Investor Presentation: Key Takeaways
ICICI Prudential AMC reported strong growth for Q2 FY27, focusing on market share leadership in active and hybrid equity segments while maintaining a 'Customer First' trust compass strategy.
Other regulatory approval announcements
All →Neogen Chemicals Regulatory Approval
Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.
Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.